×
0 0 0 0 0 0.0454545454545455 0 0
Stockreport

Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress

AKARI THERAPEUTICS PLC ADR (AKTX)  More Company Research Source: GlobeNewswire
US:NASDAQ Investor Relations: investor.akaritx.com/investor-relations
PDF Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve TrialCAPSTONE, the Phase III Naïve PNH Trial Expected to Open in Q1 2018Phase II PNH Trial Completed With Primary Endpoint MetPhase II aHUS Trial Initiated End of 2017U.S. Food and Drug Administration Fast Track Designation for resistant patients and End of Phase II Meeting for PNH Completed with Agreed Upon Phase III CAPSTONE Trial DesignManagement to Host Conference Call Today at 8:30 a.m. ET NEW YORK and LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, today announces its financial results for the fourth quarter and full year ended December 31, 2017 and highlights progress on its clinical development programs. “We made significant progress in 2017 advancing our lead product candidate, Coversin™ [Read more]

IMPACT SNAPSHOT EVENT TIME: AKTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
AKTX alerts
from News Quantified
Opt-in for
AKTX alerts

from News Quantified
Opt-in for
AKTX alerts

from News Quantified